---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-268165"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T03:21:04.930504+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Neumora Q3 net loss $53.0M; cash $519.5M; navacaprant Phase 3 on track

## Summary
- Net loss of $53.0M in Q3 2023 vs. $29.3M in Q3 2022, driven by higher R&D costs ($41.6M vs. $22.5M).
- Cash, cash equivalents and marketable securities of $519.5M as of Sept 30, 2023; expected to fund operations into 2026.
- Navacaprant (KOR antagonist) Phase 3 KOASTAL trials ongoing; KOASTAL-1 topline data expected H2 2024; bipolar depression trial planned H1 2024.
- Completed IPO in Sept 2023; shares began trading on Nasdaq under NMRA; raised over $850M since inception.
- Appointed Robert Lenz, M.D., Ph.D., as EVP, head of R&D in October 2023.

## SEC filing metadata
- accession: 0001193125-23-268165
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312523268165/0001193125-23-268165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312523268165/d518702d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-268165
- JSON: https://secwatch.observer/filing/0001193125-23-268165.json
- Plain text: https://secwatch.observer/filing/0001193125-23-268165.txt

## Key facts
- Earnings Releases
  Neumora Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $53.0 million.
  - Period: the third quarter ended September 30, 2023
  - Net income: $53.0 million
  - Result: reported results
  source text: The Company reported a net loss of $53.0 million for the third quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312523268165/0001193125-23-268165-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.